Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-10-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/2/e000437corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
by: Lin Shen, et al.
Published: (2020-05-01)

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
by: Yun Zhang, et al.
Published: (2020-05-01)

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial
by: Run-Cong Nie, et al.
Published: (2025-02-01)

Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors
by: Yan Wang, et al.
Published: (2025-06-01)

Comparative efficacy of tislelizumab plus lenvatinib and tislelizumab alone against advanced hepatocellular carcinoma after lenvatinib failure: a real-world study
by: Jiajin Yang, et al.
Published: (2025-04-01)

Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact
by: Tian Yu, et al.
Published: (2025-05-01)

Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
by: Gabriel Capellá, et al.
Published: (2022-03-01)

Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial
by: Michael Lee, et al.
Published: (2024-10-01)

Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
by: Gang Chen, et al.
Published: (2025-02-01)

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
by: Chia-Chi Lin, et al.
Published: (2024-12-01)

First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
by: Peter Ellmark, et al.
Published: (2025-01-01)

Case Report: Robust and durable response to the combination of tislelizumab and chemotherapy in advanced thymic epithelial tumors: a case series
by: Lantian Zhang, et al.
Published: (2025-05-01)

Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial
by: Ying Zhu, et al.
Published: (2025-02-01)

First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors
by: David Turner, et al.
Published: (2025-08-01)

Correction: Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer—an open-label phase 2 randomized controlled trial
by: Vinod K. Ramani, et al.
Published: (2025-08-01)

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors
by: Russell J. Schilder, et al.
Published: (2025-03-01)

Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study
by: Glenwood Goss, et al.
Published: (2025-05-01)

A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
by: Yasutoshi Kuboki, et al.
Published: (2025-05-01)

Correction: Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study
Published: (2022-10-01)

Correction: Case Report: Regenerative hepatic pseudotumor induced by tislelizumab in a lung cancer patient
by: Wenrui Wang, et al.
Published: (2025-07-01)

Diacerein for osteoarthritis: An open-label comparative trial
by: L. V. Luchikhina, et al.
Published: (2016-03-01)

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
Published: (2020-05-01)

A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease
by: Hong Ren, et al.
Published: (2025-08-01)

Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors
by: Daphne W. M. Voogd, et al.
Published: (2025-05-01)

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial
by: Mirella Nardo, et al.
Published: (2025-02-01)

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
by: Howard Streicher, et al.
Published: (2022-03-01)

Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study
by: Gang Yuan, et al.
Published: (2024-01-01)

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trialResearch in context
by: Abha A. Gupta, et al.
Published: (2025-01-01)

Tislelizumab-induced anaphylactic shock: a case report
by: Haiyu Niu, et al.
Published: (2025-07-01)

Case report: Multi-organ injuries induced by tislelizumab
by: Man Yuan, et al.
Published: (2025-02-01)

Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation
by: Caroline Pilon, et al.
Published: (2024-11-01)

Intravenous esketamine in pediatric Rett syndrome: An open-label, early phase 1 pilot study
by: Huiping Li, et al.
Published: (2025-03-01)

Polymeric Micellar Paclitaxel Plus Cisplatin Combined With Tislelizumab as the First‐Line Treatment of Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study
by: Xiaoyou Li, et al.
Published: (2025-04-01)

First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study
by: Guoming Shi, et al.
Published: (2025-08-01)

Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants
by: Yulei He, et al.
Published: (2025-12-01)

Unexpected outcomes of tislelizumab treatment in thoracic metastasis of malignant phyllodes tumors: a case report and literature review
by: Yihao Liu, et al.
Published: (2025-04-01)

Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors
by: Zihong Chen, et al.
Published: (2025-07-01)

Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial
by: Wei Yang, et al.
Published: (2025-04-01)

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors
by: Matthew Burge, et al.
Published: (2023-01-01)

Case Report: Immune-mediated acute liver failure induced by tislelizumab in a patient with advanced cervical cancer
by: Chaoxia Liu, et al.
Published: (2025-08-01)

Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Similar Items

Similar Items